Last updated: April 24, 2026
Who Manufactures and Supplies Leukeran (Chlorambucil)?
Leukeran is the branded name for chlorambucil, an established oncology alkylating agent. Supply is split between (i) the originator brand supply chain in each geography and (ii) generic API and finished-dose manufacturers that sell under marketing authorizations held locally.
Which companies supply Leukeran in the US/EU/UK?
Sufficient sourcing detail is not available to produce a complete, accurate supplier list for Leukeran across geographies.
What can be stated from the drug identity itself
| Item |
Leukeran |
| Generic name |
Chlorambucil |
| Drug class |
Alkylating agent (nitrogen mustard) |
| Typical regulatory status |
Prescription-only oncology drug |
| Core supply reality |
Multiple suppliers due to generic availability in most markets |
Why a definitive “supplier list” cannot be completed from available information
Leukeran is distributed through different channels by market (wholesalers, local distributors, national marketing authorization holders, and generic packers). Without market-specific regulatory and labeling data for each jurisdiction, a single global list of suppliers would be incomplete or potentially incorrect.
Supply-chain view that is usable for decisioning
Even without a jurisdiction-by-jurisdiction supplier table, business teams can map supply risk using a standardized checklist:
1) Finished-dose marketing authorization holder (MAH) by market
- Identify the MAH listed on the local product label/SmPC
- Track the packaging site where the finished dose is manufactured
2) API manufacture
- For chlorambucil generics, API sourcing can shift between:
- API manufacturers listed in regulatory dossiers
- Contract manufacturing and re-pack channels
- API supply is often more concentrated than finished-dose supply.
3) Distribution channel and cold-chain requirements
- Chlorambucil products are generally handled as ambient-stable oncology pharmaceuticals, but distribution conditions can vary by local requirements and pack design.
4) Brand vs generic supply
- “Leukeran” supply depends on whether a given market still carries the original brand versus generic substitutes that dominate volume.
What to do operationally
A complete supplier mapping must be built from:
- local product labels (MAH and packager)
- regulatory product databases per jurisdiction
- API manufacturer statements tied to specific marketing authorizations
Key Takeaways
- Leukeran is chlorambucil, and the supply base is market-dependent.
- A global, single supplier list cannot be produced accurately without jurisdiction-specific labeling and regulatory references.
- The correct structure is to map MAH (finished dose) and API manufacturer by each target market.
FAQs
-
Is Leukeran chlorambucil or a different drug?
Leukeran is the brand name for chlorambucil.
-
Are there multiple suppliers for chlorambucil?
Yes. Generic chlorambucil is widely available, so suppliers differ by market and marketing authorization.
-
Who actually supplies Leukeran to hospitals?
Hospitals typically receive product through wholesalers and local distributors tied to the market’s MAH and packager.
-
Does API sourcing affect Leukeran availability?
Yes. API availability and manufacturing capacity can affect lead times and product continuity, especially where generics hold most of the volume.
-
Can one supplier list cover all countries?
No. Supplier responsibility changes by jurisdiction (MAH, packager, distributor) and by time (manufacturing transfers).
References
[1] FDA. (n.d.). Drug databases: Leukeran (chlorambucil) label and related information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov
[2] EMA. (n.d.). European public assessment reports (EPAR): chlorambucil / Leukeran-related product information. European Medicines Agency. https://www.ema.europa.eu
[3] DailyMed. (n.d.). Leukeran (chlorambucil) prescribing information and label. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov
